HRP20100621T1 - Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida - Google Patents
Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida Download PDFInfo
- Publication number
- HRP20100621T1 HRP20100621T1 HR20100621T HRP20100621T HRP20100621T1 HR P20100621 T1 HRP20100621 T1 HR P20100621T1 HR 20100621 T HR20100621 T HR 20100621T HR P20100621 T HRP20100621 T HR P20100621T HR P20100621 T1 HRP20100621 T1 HR P20100621T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- methylpyrazin
- pyridine
- methoxy
- phenyl
- Prior art date
Links
- -1 3-methoxy-5-methylpyrazin-2yl Chemical group 0.000 title 1
- 150000002169 ethanolamines Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 title 1
- MUVIXLBNMQPGRV-UHFFFAOYSA-N 2-aminoethanol;n-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide Chemical compound NCCO.COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 MUVIXLBNMQPGRV-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 4
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229910016523 CuKa Inorganic materials 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514743.4A GB0514743D0 (en) | 2005-07-19 | 2005-07-19 | Salt |
| PCT/GB2006/002654 WO2007010235A1 (en) | 2005-07-19 | 2006-07-17 | Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100621T1 true HRP20100621T1 (hr) | 2010-12-31 |
Family
ID=34897419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100621T HRP20100621T1 (hr) | 2005-07-19 | 2010-11-16 | Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20080221124A1 (sl) |
| EP (1) | EP1904490B1 (sl) |
| JP (1) | JP5085544B2 (sl) |
| KR (1) | KR20080031042A (sl) |
| CN (1) | CN101223165B (sl) |
| AT (1) | ATE482952T1 (sl) |
| AU (1) | AU2006271420B2 (sl) |
| CA (1) | CA2615596A1 (sl) |
| CY (1) | CY1110942T1 (sl) |
| DE (1) | DE602006017220D1 (sl) |
| DK (1) | DK1904490T3 (sl) |
| ES (1) | ES2351442T3 (sl) |
| GB (1) | GB0514743D0 (sl) |
| HK (1) | HK1118276A1 (sl) |
| HR (1) | HRP20100621T1 (sl) |
| IL (1) | IL188389A0 (sl) |
| MX (1) | MX2008000889A (sl) |
| NO (1) | NO20080053L (sl) |
| PL (1) | PL1904490T3 (sl) |
| PT (1) | PT1904490E (sl) |
| SI (1) | SI1904490T1 (sl) |
| WO (1) | WO2007010235A1 (sl) |
| ZA (1) | ZA200800328B (sl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| GB0914287D0 (en) * | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
| CN102491973A (zh) * | 2011-12-15 | 2012-06-13 | 南京友杰医药科技有限公司 | Zd-4054的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US20020055457A1 (en) * | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| US20030092757A1 (en) * | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| DE60207890T2 (de) * | 2001-12-18 | 2006-08-10 | Astrazeneca Ab | Neue verbindungen |
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
-
2005
- 2005-07-19 GB GBGB0514743.4A patent/GB0514743D0/en not_active Ceased
-
2006
- 2006-07-17 AU AU2006271420A patent/AU2006271420B2/en not_active Ceased
- 2006-07-17 DE DE602006017220T patent/DE602006017220D1/de active Active
- 2006-07-17 DK DK06755779.3T patent/DK1904490T3/da active
- 2006-07-17 EP EP06755779A patent/EP1904490B1/en active Active
- 2006-07-17 US US11/996,005 patent/US20080221124A1/en not_active Abandoned
- 2006-07-17 AT AT06755779T patent/ATE482952T1/de active
- 2006-07-17 ES ES06755779T patent/ES2351442T3/es active Active
- 2006-07-17 PT PT06755779T patent/PT1904490E/pt unknown
- 2006-07-17 CA CA002615596A patent/CA2615596A1/en not_active Abandoned
- 2006-07-17 MX MX2008000889A patent/MX2008000889A/es active IP Right Grant
- 2006-07-17 CN CN2006800261471A patent/CN101223165B/zh not_active Expired - Fee Related
- 2006-07-17 JP JP2008522051A patent/JP5085544B2/ja not_active Expired - Fee Related
- 2006-07-17 PL PL06755779T patent/PL1904490T3/pl unknown
- 2006-07-17 SI SI200630823T patent/SI1904490T1/sl unknown
- 2006-07-17 WO PCT/GB2006/002654 patent/WO2007010235A1/en active Application Filing
- 2006-07-17 KR KR1020087002607A patent/KR20080031042A/ko not_active Application Discontinuation
-
2007
- 2007-12-24 IL IL188389A patent/IL188389A0/en unknown
-
2008
- 2008-01-04 NO NO20080053A patent/NO20080053L/no not_active Application Discontinuation
- 2008-01-10 ZA ZA200800328A patent/ZA200800328B/xx unknown
- 2008-08-21 HK HK08109379.4A patent/HK1118276A1/xx not_active IP Right Cessation
-
2010
- 2010-11-16 HR HR20100621T patent/HRP20100621T1/hr unknown
- 2010-11-25 CY CY20101101068T patent/CY1110942T1/el unknown
-
2011
- 2011-07-25 US US13/189,818 patent/US20120101109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20080053L (no) | 2008-04-16 |
| IL188389A0 (en) | 2008-04-13 |
| HK1118276A1 (en) | 2009-02-06 |
| KR20080031042A (ko) | 2008-04-07 |
| PL1904490T3 (pl) | 2011-02-28 |
| DE602006017220D1 (de) | 2010-11-11 |
| ATE482952T1 (de) | 2010-10-15 |
| CA2615596A1 (en) | 2007-01-25 |
| US20120101109A1 (en) | 2012-04-26 |
| SI1904490T1 (sl) | 2010-12-31 |
| ES2351442T3 (es) | 2011-02-04 |
| CN101223165A (zh) | 2008-07-16 |
| CN101223165B (zh) | 2011-10-19 |
| MX2008000889A (es) | 2008-03-18 |
| JP2009501774A (ja) | 2009-01-22 |
| PT1904490E (pt) | 2010-11-18 |
| EP1904490B1 (en) | 2010-09-29 |
| JP5085544B2 (ja) | 2012-11-28 |
| WO2007010235A8 (en) | 2008-03-13 |
| ZA200800328B (en) | 2008-12-31 |
| DK1904490T3 (da) | 2010-12-13 |
| AU2006271420A1 (en) | 2007-01-25 |
| GB0514743D0 (en) | 2005-08-24 |
| EP1904490A1 (en) | 2008-04-02 |
| AU2006271420B2 (en) | 2010-09-23 |
| CY1110942T1 (el) | 2015-06-10 |
| WO2007010235A1 (en) | 2007-01-25 |
| US20080221124A1 (en) | 2008-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518110A5 (sl) | ||
| HRP20171748T1 (hr) | 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| EA200800502A1 (ru) | Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения | |
| EP3856345A1 (en) | Process of manufacture of a compound for inhibiting the activity of shp2 | |
| JP2014511840A5 (sl) | ||
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2011126896A5 (sl) | ||
| JP2016504365A5 (sl) | ||
| JP2020517616A5 (sl) | ||
| CN103327977B (zh) | 恶液质的治疗或预防剂 | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| JP2014527042A5 (sl) | ||
| HRP20120490T1 (hr) | Spojevi za inhibiciju napredovanja mitoze | |
| MXPA05011739A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarinicos m3. | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20100678T1 (hr) | Derivati heteroariluree korisni kao inhibitori chk1 | |
| HRP20100621T1 (hr) | Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida | |
| HK1109767A1 (en) | Quaternary ammonium salts as m3 antagonists | |
| EP2342198B1 (en) | A diphosphate salt of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | |
| UA89905C2 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ | |
| HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| JP2021501756A5 (sl) |